Sun Qinyu, Deng Yifan, Yu Jiling, Zhang Zhaoyuan, Cao Gan, Yang Tianxiao, Fang Zhen, Ji Jun, He Shenghu, Zhang Jing
{"title":"经皮腔内室间隔心肌消融治疗肥厚性心肌病的疗效和安全性：系统评价和荟萃分析","authors":"Sun Qinyu, Deng Yifan, Yu Jiling, Zhang Zhaoyuan, Cao Gan, Yang Tianxiao, Fang Zhen, Ji Jun, He Shenghu, Zhang Jing","doi":"10.1155/ijcp/8869127","DOIUrl":null,"url":null,"abstract":"<p><b>Background:</b> Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM).</p><p><b>Objective:</b> To systematically evaluate the efficacy and safety of PTSMA in patients with HCM.</p><p><b>Methods:</b> A systematic searching of Pubmed, Web of Science, Embase, and Cochrane Library databases was conducted for screening of studies conducted from library building to October 20, 2024 involving the treatment of PTSMA in patients with HCM. Two investigators independently screened the literature, extracted the data, and evaluated the risk of bias in the included study; meta-analysis was performed using Stata14.0 software.</p><p><b>Results:</b> A total of 10 literature articles were included. The mean LVOT PG reduction of 1910 patients with HCM after PTSMA treatment was 47.74 mmHg (95% CI: 39.75–55.72, <i>p</i> < 0.01). The mean reduction in the maximum septal thickness was 4.76 mm (95% CI: 3.67–5.85, <i>p</i> < 0.01). The incidence of the central package effusion in surgical complications was 2% (95% CI: 0%–3%, <i>p</i> < 0.01). The incidence of the left bundle branch block was 19% (95% CI: 5%–39%, <i>p</i> < 0.01).The incidence of right bundle branch block was 9% (95% CI: 4%–17%, <i>p</i> < 0.01). The incidence of the all-cause death from follow-up events was 2% (95% CI: 0%–5%, <i>p</i> = 0.01). The incidence of pacemaker implantation was 6% (95% CI: 4%–10%, <i>p</i> < 0.01).</p><p><b>Conclusion:</b> PTSMA is effective and safe in treating patients with HCM.</p>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2025 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ijcp/8869127","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Percutaneous Transluminal Septal Myocardial Ablation Treating Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis\",\"authors\":\"Sun Qinyu, Deng Yifan, Yu Jiling, Zhang Zhaoyuan, Cao Gan, Yang Tianxiao, Fang Zhen, Ji Jun, He Shenghu, Zhang Jing\",\"doi\":\"10.1155/ijcp/8869127\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>Background:</b> Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM).</p><p><b>Objective:</b> To systematically evaluate the efficacy and safety of PTSMA in patients with HCM.</p><p><b>Methods:</b> A systematic searching of Pubmed, Web of Science, Embase, and Cochrane Library databases was conducted for screening of studies conducted from library building to October 20, 2024 involving the treatment of PTSMA in patients with HCM. Two investigators independently screened the literature, extracted the data, and evaluated the risk of bias in the included study; meta-analysis was performed using Stata14.0 software.</p><p><b>Results:</b> A total of 10 literature articles were included. The mean LVOT PG reduction of 1910 patients with HCM after PTSMA treatment was 47.74 mmHg (95% CI: 39.75–55.72, <i>p</i> < 0.01). The mean reduction in the maximum septal thickness was 4.76 mm (95% CI: 3.67–5.85, <i>p</i> < 0.01). The incidence of the central package effusion in surgical complications was 2% (95% CI: 0%–3%, <i>p</i> < 0.01). The incidence of the left bundle branch block was 19% (95% CI: 5%–39%, <i>p</i> < 0.01).The incidence of right bundle branch block was 9% (95% CI: 4%–17%, <i>p</i> < 0.01). The incidence of the all-cause death from follow-up events was 2% (95% CI: 0%–5%, <i>p</i> = 0.01). The incidence of pacemaker implantation was 6% (95% CI: 4%–10%, <i>p</i> < 0.01).</p><p><b>Conclusion:</b> PTSMA is effective and safe in treating patients with HCM.</p>\",\"PeriodicalId\":13782,\"journal\":{\"name\":\"International Journal of Clinical Practice\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ijcp/8869127\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/ijcp/8869127\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ijcp/8869127","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：经皮腔内室间隔心肌消融（PTSMA）是治疗梗阻性肥厚性心肌病（HCM）的有创治疗措施之一。目的：系统评价PTSMA治疗HCM患者的疗效和安全性。方法：系统检索Pubmed、Web of Science、Embase和Cochrane图书馆数据库，筛选从图书馆建设到2024年10月20日进行的涉及HCM患者PTSMA治疗的研究。两名研究者独立筛选文献、提取数据并评估纳入研究的偏倚风险；采用Stata14.0软件进行meta分析。结果：共纳入文献10篇。1910例HCM患者经PTSMA治疗后平均LVOT PG降低47.74 mmHg （95% CI: 39.75-55.72, p < 0.01）。最大间隔厚度平均减少4.76 mm （95% CI: 3.67-5.85, p < 0.01）。手术并发症中中央包积液的发生率为2% （95% CI: 0% ~ 3%, p < 0.01）。左束支阻滞发生率为19% （95% CI: 5% ~ 39%, p < 0.01）。右束支阻滞发生率为9% （95% CI: 4% ~ 17%, p < 0.01）。随访事件的全因死亡发生率为2% （95% CI: 0%-5%, p = 0.01）。起搏器植入发生率为6% （95% CI: 4% ~ 10%, p < 0.01）。结论：PTSMA治疗HCM有效、安全。
Efficacy and Safety of Percutaneous Transluminal Septal Myocardial Ablation Treating Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM).
Objective: To systematically evaluate the efficacy and safety of PTSMA in patients with HCM.
Methods: A systematic searching of Pubmed, Web of Science, Embase, and Cochrane Library databases was conducted for screening of studies conducted from library building to October 20, 2024 involving the treatment of PTSMA in patients with HCM. Two investigators independently screened the literature, extracted the data, and evaluated the risk of bias in the included study; meta-analysis was performed using Stata14.0 software.
Results: A total of 10 literature articles were included. The mean LVOT PG reduction of 1910 patients with HCM after PTSMA treatment was 47.74 mmHg (95% CI: 39.75–55.72, p < 0.01). The mean reduction in the maximum septal thickness was 4.76 mm (95% CI: 3.67–5.85, p < 0.01). The incidence of the central package effusion in surgical complications was 2% (95% CI: 0%–3%, p < 0.01). The incidence of the left bundle branch block was 19% (95% CI: 5%–39%, p < 0.01).The incidence of right bundle branch block was 9% (95% CI: 4%–17%, p < 0.01). The incidence of the all-cause death from follow-up events was 2% (95% CI: 0%–5%, p = 0.01). The incidence of pacemaker implantation was 6% (95% CI: 4%–10%, p < 0.01).
Conclusion: PTSMA is effective and safe in treating patients with HCM.
期刊介绍：
IJCP is a general medical journal. IJCP gives special priority to work that has international appeal.
IJCP publishes:
Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion]
Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion]
Study design and interpretation. Example. [Always peer reviewed]
Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed]
Meta-analyses. [Always peer reviewed]
Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed]
Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed]
''How to…'' papers. Example. [Always peer reviewed]
Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed]
Letters. [Peer reviewed at the editor''s discretion]
International scope
IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
